Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 278

1.

Health and economic impact of human papillomavirus 16 and 18 vaccination of preadolescent girls and cervical cancer screening of adult women in Peru.

Goldie SJ, Levin C, Mosqueira-Lovón NR, Ortendahl J, Kim J, O'Shea M, Diaz Sanchez M, Mendoza Araujo MA.

Rev Panam Salud Publica. 2012 Dec;32(6):426-34.

2.

Cost-effectiveness of human papillomavirus vaccination and cervical cancer screening in Thailand.

Sharma M, Ortendahl J, van der Ham E, Sy S, Kim JJ.

BJOG. 2012 Jan;119(2):166-76. doi: 10.1111/j.1471-0528.2011.02974.x. Epub 2011 Apr 12.

3.

Cost-effectiveness of cervical cancer prevention in Central and Eastern Europe and Central Asia.

Berkhof J, Bogaards JA, Demirel E, Diaz M, Sharma M, Kim JJ.

Vaccine. 2013 Dec 31;31 Suppl 7:H71-9. doi: 10.1016/j.vaccine.2013.04.086.

PMID:
24332299
4.

Health and economic outcomes of HPV 16,18 vaccination in 72 GAVI-eligible countries.

Goldie SJ, O'Shea M, Campos NG, Diaz M, Sweet S, Kim SY.

Vaccine. 2008 Jul 29;26(32):4080-93. doi: 10.1016/j.vaccine.2008.04.053. Epub 2008 May 15.

PMID:
18550229
5.

Health and economic impact of HPV 16 and 18 vaccination and cervical cancer screening in India.

Diaz M, Kim JJ, Albero G, de Sanjosé S, Clifford G, Bosch FX, Goldie SJ.

Br J Cancer. 2008 Jul 22;99(2):230-8. doi: 10.1038/sj.bjc.6604462. Epub 2008 Jul 8.

6.

Model-based impact and cost-effectiveness of cervical cancer prevention in sub-Saharan Africa.

Kim JJ, Campos NG, O'Shea M, Diaz M, Mutyaba I.

Vaccine. 2013 Dec 29;31 Suppl 5:F60-72. doi: 10.1016/j.vaccine.2012.07.093.

PMID:
24331749
7.

Incremental cost-effectiveness evaluation of vaccinating girls against cervical cancer pre- and post-sexual debut in Belgium.

Demarteau N, Van Kriekinge G, Simon P.

Vaccine. 2013 Aug 20;31(37):3962-71. doi: 10.1016/j.vaccine.2013.06.008. Epub 2013 Jun 15.

8.

Mathematical models of cervical cancer prevention in the Asia Pacific region.

Goldie SJ, Diaz M, Kim SY, Levin CE, Van Minh H, Kim JJ.

Vaccine. 2008 Aug 19;26 Suppl 12:M17-29. doi: 10.1016/j.vaccine.2008.06.018.

PMID:
18945411
10.

Health economic analysis of human papillomavirus vaccines in women of Chile: perspective of the health care payer using a Markov model.

Gomez JA, Lepetic A, Demarteau N.

BMC Public Health. 2014 Nov 26;14:1222. doi: 10.1186/1471-2458-14-1222.

11.

An extended cost-effectiveness analysis of publicly financed HPV vaccination to prevent cervical cancer in China.

Levin CE, Sharma M, Olson Z, Verguet S, Shi JF, Wang SM, Qiao YL, Jamison DT, Kim JJ.

Vaccine. 2015 Jun 4;33(24):2830-41. doi: 10.1016/j.vaccine.2015.02.052. Epub 2015 Mar 12.

12.

Cost-effectiveness evaluation of a quadrivalent human papillomavirus vaccine in Belgium.

Annemans L, Rémy V, Oyee J, Largeron N.

Pharmacoeconomics. 2009;27(3):231-45. doi: 10.2165/00019053-200927030-00006.

PMID:
19354343
13.

Cost-effectiveness analysis of the introduction of the human papillomavirus vaccine in Honduras.

Aguilar IB, Mendoza LO, García O, Díaz I, Figueroa J, Duarte RM, Perdomo G, Garcia AG, Janusz CB.

Vaccine. 2015 May 7;33 Suppl 1:A167-73. doi: 10.1016/j.vaccine.2014.12.067.

PMID:
25919157
14.

A case study using the United Republic of Tanzania: costing nationwide HPV vaccine delivery using the WHO Cervical Cancer Prevention and Control Costing Tool.

Hutubessy R, Levin A, Wang S, Morgan W, Ally M, John T, Broutet N.

BMC Med. 2012 Nov 13;10:136. doi: 10.1186/1741-7015-10-136.

15.

Introducing HPV vaccine and scaling up screening procedures to prevent deaths from cervical cancer in Japan: a cost-effectiveness analysis.

Yamamoto N, Mori R, Jacklin P, Osuga Y, Kawana K, Shibuya K, Taketani Y.

BJOG. 2012 Jan;119(2):177-86. doi: 10.1111/j.1471-0528.2011.03036.x. Epub 2011 Jul 28.

16.

Model-based impact and cost-effectiveness of cervical cancer prevention in the Extended Middle East and North Africa (EMENA).

Kim JJ, Sharma M, O'Shea M, Sweet S, Diaz M, Sancho-Garnier H, Seoud M.

Vaccine. 2013 Dec 30;31 Suppl 6:G65-77. doi: 10.1016/j.vaccine.2012.06.096.

PMID:
24331822
17.

Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine.

Goldie SJ, Kohli M, Grima D, Weinstein MC, Wright TC, Bosch FX, Franco E.

J Natl Cancer Inst. 2004 Apr 21;96(8):604-15.

PMID:
15100338
18.

Cost-effectiveness of HPV vaccination in Belize.

Walwyn L, Janusz CB, Clark AD, Prieto E, Waight E, Largaespada N.

Vaccine. 2015 May 7;33 Suppl 1:A174-81. doi: 10.1016/j.vaccine.2014.12.042.

PMID:
25919158
19.

Cost-effectiveness analysis of human papillomavirus vaccination in the Netherlands.

de Kok IM, van Ballegooijen M, Habbema JD.

J Natl Cancer Inst. 2009 Aug 5;101(15):1083-92. doi: 10.1093/jnci/djp183. Epub 2009 Jul 1.

PMID:
19571256
20.

Mathematical models of cervical cancer prevention in Latin America and the Caribbean.

Goldie SJ, Diaz M, Constenla D, Alvis N, Andrus JK, Kim SY.

Vaccine. 2008 Aug 19;26 Suppl 11:L59-72. doi: 10.1016/j.vaccine.2008.05.063.

PMID:
18945403

Supplemental Content

Support Center